Overview Apremilast 30 mg BID Combined With Dupilumab Status: Recruiting Trial end date: 2022-12-01 Target enrollment: Participant gender: Summary Open label phase 2 investigational study of efficacy and safety of apremilast 30 mg BID in chronic atopic dermatitis when added to the FDA approved treatment dupilumab for atopic dermatitis that is not providing adequate clinical responses. Phase: Phase 2 Details Lead Sponsor: Tufts Medical CenterCollaborator: AmgenTreatments: ApremilastThalidomide